drugset / Trial / NCT00146380

A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding

NCT00146380

Phase 2 Completed 520 enrolled Centers for Disease Control and Prevention
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of the study is to demonstrate that a regimen using highly active antiretroviral therapy (HAART) to maximally suppress maternal viral load in the late antenatal period and during the first six months of lactation is safe, effective and can be implemented in resource poor settings in order to reduce the risk of HIV transmission to the infant.

Timeline

Start
2003-07
Primary completion
2009-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamivudine Other / unclassified 150 mg Oral
Subject Nelfinavir Other / unclassified 1250 mg Oral
Subject Nevirapine Small molecule 200 mg Oral
Subject Zidovudine Small molecule 300 mg Oral